Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years
Metastatic colorectal cancer
Progression on or following standard therapy, or no standard therapy (phase Ib). Progression on or following at least 2-prior fluoropyrimidine-containing chemotherapy regimens (phase II)
Written documentation of mutant or wild-type RAS
Life expectancy ≥ 3 months
ECOG performance status ≤ 2
You may not be if
Phase II arms 1 and 4 only: previous treatment with cetuximab, panitumumab, and/or other EGFR inhibitors
Previous treatment with MEK-inhibitors
History of severe infusion reactions to monoclonal antibodies.
Symptomatic or untreated leptomeningeal disease
Symptomatic brain metastasis
Current evidence of retinal disease; history of CSR, RVO or ophthalmopathy as assessed by ophthalmologic examination at baseline that would be considered a risk factor for CSR/RVO and history of keratitis.
Acute or chronic pancreatitis
Clinically significant cardiac disease
Not adequate hematologic, renal and hepatic function
Clareo Health | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
